Brought to you by 
RNAi company Dicerna Pharmaceuticals nets $96.3mm in IPO
06 Feb 2014
Executive Summary
Five months after raising $60mm in Series C funds from its venture backers, Dicerna Pharmaceuticals Inc. (gene silencing in rare liver diseases and genetically defined cancers) netted $96.3mm in its initial public offering of 6.9mm shares (including the overallotment) for $15. Earlier in the month, the company planned to sell 5mm shares at $11-13, and then upped the proposed price to $14.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
- Site Specific
-
Drug Delivery
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com